NUCB2

Across TCGA pan-cancer cohorts, NUCB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NUCB2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NUCB2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUCB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where NUCB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.674	0.928	.013	13	view →
LSCC	OS	Quartile	All	0.787	0.995	.008	12	view →
UCEC	DFS	Tertile	All	0.974	0.826	.013	10	view →
PDAC	DFS	Median	II,III,IV	0.465	0.312	.014	10	view →
GBM	DFS	Quartile	All	0.586	0.237	.012	4	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NUCB2–CCRCC (OS)

Open the CCRCC breakdown →